GlassScriptPhysician profile
Steven L Hubert
NPI 1770586430
$5,529.23
in general payments reported to CMS, 2019-2025
36 companies · $745 in 2025
The $745 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $626 · 2021: $498 · 2022: $1,513 · 2023: $617 · 2024: $1,103 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432 · Consulting Fee: $560 · Gift: $400 · Education: $73.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.88 |
| Consulting Fee | $560.00 |
| Gift | $400.00 |
| Education | $73.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,072.42 | 2019-2025 | |
| Sekisui Diagnostics LLC | $710.00 | 2022-2025 | |
| Becton, Dickinson and Company | $560.00 | 2024 | |
| Zoll Medical Corporation | $490.00 | 2022 | |
| Janssen Biotech, INC. | $444.39 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $349.46 | 2019-2025 | Ilumya, Winlevi |
| Regeneron Healthcare Solutions, INC. | $240.54 | 2020-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $187.18 | 2023-2024 | Vtama |
| Eli Lilly and Company | $175.00 | 2021 | |
| Incyte Corporation | $137.59 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $127.23 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $109.88 | 2019-2024 | |
| Comsort, INC | $100.00 | 2019 | |
| Leo Pharma INC. | $87.14 | 2019-2024 | Adbry |
| Epi Health, LLC | $76.64 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $64.82 | 2019-2025 | |
| Ucb, INC. | $62.99 | 2019-2022 | |
| Genzyme Corporation | $62.67 | 2020-2024 | |
| Paratek Pharmaceuticals, INC. | $62.42 | 2023-2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.95 | 2019-2021 | |
| Amgen INC. | $51.07 | 2021-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $44.96 | 2023-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $43.72 | 2020-2023 | |
| Journey Medical Corporation | $30.57 | 2019-2022 | |
| Sebela Pharmaceuticals INC. | $28.65 | 2020-2022 | |
| Organon LLC | $26.40 | 2023-2025 | Hadlima, Vtama |
| Botanix Sb INC | $16.59 | 2025 | Sofdra |
| Dermira, INC. | $14.35 | 2019 | |
| Springworks Therapeutics, INC. | $14.03 | 2025 | Gomekli |
| Merck Sharp & Dohme LLC | $13.16 | 2019 | |
| Galderma Laboratories, L.P. | $13.11 | 2019 | |
| Encore Dermatology INC. | $12.50 | 2020 | |
| Genentech USA, INC. | $12.03 | 2021 | |
| Almirall LLC | $11.16 | 2020 | |
| Vyne Pharmaceuticals INC. | $11.15 | 2020 | |
| Prugen, INC. Pharmaceuticals | $9.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.